Targeting KRAS mutations and immune suppression in pancreatic cancer
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
This study is looking at how a new treatment for pancreatic cancer that targets a specific mutation can help your immune system fight the tumors better, and it aims to find the best way to combine this treatment with other therapies to improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11035133 on NIH RePORTER |
What this research studies
This research investigates how targeting KRAS mutations in pancreatic cancer can enhance the immune response against tumors. It employs advanced techniques such as transcriptomic, proteomic, and metabolomic analyses in both human and animal models to understand the effects of KRASG12C inhibitors. The goal is to identify how these inhibitors can be combined with immune checkpoint blockade therapies to improve treatment outcomes for patients with pancreatic ductal adenocarcinoma. By understanding the metabolic changes and immune responses triggered by these treatments, the research aims to develop more effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
Not a fit: Patients with pancreatic cancer who do not have KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer by enhancing their immune response against tumors.
How similar studies have performed: Other research has shown promising results with similar approaches targeting KRAS mutations and immune modulation, indicating potential for success in this area.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Radu, Caius Gabriel — University of California Los Angeles
- Study coordinator: Radu, Caius Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.